1 research outputs found
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
- Author
- A Coulter
- AB Hauber
- AS Kesselheim
- AS Pickard
- D Marshall
- D Stacey
- D. Cassiman
- DA Hensher
- DA Hensher
- DS Pushparajah
- E Lancsar
- E Minvielle
- ED Kakkis
- European Medicines Agency (EMA)
- European Medicines Agency (EMA)
- European Medicines Agency (EMA)
- European Medicines Agency (EMA)
- European Medicines Agency (EMA)
- EW Bekker-Grob de
- FR Johnson
- G Andrews
- Genetic Alliance UK
- HG Eichler
- HG Eichler
- HL Peay
- J Louviere
- J Orme
- J Woodcock
- J Yu
- J Yu
- J Yu
- JF Bridges
- JF Bridges
- K Train
- L Frank
- M Douglas
- M Douglas
- M Harrison
- M Ryan
- M Ryan
- M Ryan
- M. Morgan
- M. Vandebroek
- MCJ Bliemer
- MJ Barry
- MK Walton
- National Organization for Rare Disorders (NORD)
- NJ Schork
- Parent Project Muscular Dystrophy
- R Kessels
- S Chakradhar
- S Eaton
- S Krimsky
- S. Aymé
- S. Simoens
- SJ Bartlett
- T. Morel
- TB Ustun
- TB Ustun
- US Department of Health and Human Services FaDAF
- US Department of Health and Human Services FaDAF
- US Department of Health and Human Services FaDAF
- Publication venue
- 'Springer Science and Business Media LLC'
- Publication date
- Field of study
Full text link
